BioCentury
ARTICLE | Clinical News

DCC-3014: Ph I started

March 10, 2017 7:56 PM UTC

Deciphera began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate once-daily DCC-3014, starting at a 10 mg dose, in 28-day cycles in up to 55 patients. Malignancies includ...